Merck’s Allergy Immunotherapy Suffers Review Delay Under Gov’t Shutdown
This article was originally published in The Pink Sheet Daily
Without user fee coverage, advisory committees for Merck and Stallergenes’ new era grass allergy products must be pushed back from their scheduled November dates.
You may also be interested in...
Shutdown puts API shipments on a slow boat, but reviews of existing products can proceed with carry-over funds, even as new applications cannot be filed. CDC has largely halted its influenza program and NIH has ceased enrolling new patients in its clinical center.
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
A US FDA advisory panel feels there could be a place for Intarcia’s exenatide drug-device combo – if the company is willing to put in the work.